Sotalol is a high-risk antiarrhythmic with QT prolongation effects that require careful dental treatment planning. Coordinate with cardiology or electrophysiology before invasive procedures and evaluate use of epinephrine, anticoagulants, and interacting medications. Watch for oral effects such as xerostomia, taste disturbance, and lichenoid drug reactions in patients taking sotalol.
Sotalol is indicated for documented, life-threatening ventricular arrhythmias and for maintaining sinus rhythm in patients with highly symptomatic atrial fibrillation or flutter. It is not approved for hypertension. The medication acts by prolonging cardiac action potentials and the QT interval, and that property is central to dental safety considerations because many commonly used drugs can also affect the QT interval.
The familiar “-lol” suffix in the name can be misleading; sotalol is a reminder that a drug name does not equal a diagnosis. Dental teams should not assume sotalol behaves like ordinary antihypertensive beta-blockers.
Sotalol carries a specific initiation requirement: it cannot be legally started or restarted after any interruption outside a hospital. Per labeling, patients require a minimum of three days of inpatient cardiac monitoring, continuous ECG, and resuscitation capability before outpatient dosing. This reflects the drug’s narrow safety margin and the potential for it to induce the arrhythmia it treats.
A related agent commonly encountered on medication lists is dofetilide (Tikosyn), which shares the same hospital-initiation requirement. A patient taking sotalol should be regarded as under active electrophysiology management, and dental teams should obtain cardiac clearance before any dental procedure. In particular, do not assume local anesthetic with epinephrine is safe without checking first: as a nonselective beta-blocker, sotalol can leave epinephrine’s vasopressor effects unopposed and potentially drive blood pressure upward.
Sotalol’s oral adverse-effect profile largely reflects class effects of beta-blockers. The most frequently reported complaint is xerostomia, which warrants a caries risk assessment, salivary substitutes, topical fluoride when indicated, and closer recall intervals.
Taste disturbance, including a blunted or distorted sense of taste, has also been reported with beta-blocker therapy and should be asked about proactively.
Beta-blockers are recognized triggers for oral lichenoid drug reactions—white, reticular, or erosive lesions that mimic lichen planus. These lesions can appear months after medication initiation, so linking a new lesion with sotalol can be missed unless the medication history is reviewed against lesion onset. Any suspicious oral finding in a patient taking sotalol should be photographed, documented, and referred or biopsied as appropriate.
A patient on sotalol has already undergone hospitalization to start the medication. That fact should prompt a call to the cardiologist or EP specialist before finalizing any treatment plan—not only before surgery or sedation. Ask the cardiology team whether planned antibiotics, analgesics, and the use of epinephrine or hemostatic agents are contraindicated.
Many patients treated for atrial fibrillation or flutter also take anticoagulants to reduce stroke risk. Confirm anticoagulant status before planning any extraction or procedure with bleeding potential, and coordinate timing and management with the prescribing physician.
Prescriptions written at the end of a dental visit present the highest iatrogenic risk for patients on sotalol. Macrolide antibiotics—azithromycin, clarithromycin, and erythromycin—are independently recognized as QT-prolonging agents. Stacking a QT-prolonging antibiotic on top of sotalol can be dangerous.
Dentists should avoid macrolides and consider penicillin or amoxicillin for most dental infections, escalating to amoxicillin-clavulanate when appropriate. For penicillin-allergic patients, doxycycline is suggested. The article specifically advises against erythromycin and clindamycin when treating patients on sotalol. Always run proposed prescriptions through a drug interaction checker or consult the patient’s cardiologist before sending them.
Analgesic choices also require cardiology input: most opioids with sotalol raise the risk of severe hypotension, and hydrocodone and tramadol may further increase QT prolongation and syncope risk. A five-minute phone call to the cardiologist before prescribing can prevent emergencies.
Sotalol is not a garden-variety antihypertensive. It is a hospital-initiated, QT-sensitive, narrow-margin antiarrhythmic prescribed to patients whose hearts have previously demonstrated serious rhythm instability. A drug name can mask these clinical realities; familiar suffixes are not reliable indicators of safety in the dental setting. Reviewing the medical history carefully and making a single phone call to the cardiologist or EP team is a small step that can keep a patient out of the emergency department or worse.
The author notes a professional exchange with a cardiology pharmacist that prompted this review and highlights the value of tools such as MedAssent DDS to surface dental-relevant medication implications and interactions at chairside.